Weekly #8: Most Interesting D-Sheets from the Past Week
Week of Jun 1 – June 7, 2026 | $NURS.V, $BOSC, $PYYX
Here are the InfoArb Tear Sheets we think you should pay the most attention to, where the differences between press releases and earnings calls are dramatic because they outline new catalysts, trends, and clarify misconceptions from just reading the press release.
These summaries are created to help you speed up your research on interesting companies. They are not buy/sell recommendations.
💡 These are tear sheet summaries; click any title to read the full tear sheet.
NURS.V — Hydreight Technologies Inc. 🟢 Strong Signal
Description: U.S.-focused digital health infrastructure platform that lets med spas, telehealth operators, and DTC wellness brands launch compliant services across all 50 states. ~C$252.5M cap, C$24.9M Q1 revenue.
Set-up: After years as a “trust the platform” story, Q1 delivered the proof — revenue up 449% year over year to $24.9M, net income positive at $2.6M, and adjusted EBITDA of $3.3M — with a reaffirmed $150M minimum full-year guide at a 15–17% EBITDA margin.
Information arbitrage:
Guidance is execution, not pipeline: The $150M minimum guide excludes acquisitions, new geographies, and new enterprise partnerships, so it rests on demand the company already sees rather than deals it must win.
Operating leverage already in the print: Revenue grew 67% sequentially with no rise in operating expenses, pushing opex below 9% of revenue and expanding adjusted EBITDA margin for a third straight quarter (5.9% to 10.6% to 13.1%).
Platform onboarding compounds: New compliant categories (GLP-1s, peptides, TRT) are added once and sold across the whole partner base, so each new line is worth more than a single-customer win.
Risks: Gross margin halved on pharmacy mix and the quarter burned $4.9M of operating cash on receivables despite positive net income, so cash conversion — not growth — is the open question; the thesis also leans on regulation staying a tailwind rather than restricting categories.
BOSC — B.O.S. Better Online Solutions Ltd. 🟡 Moderate Signal
Description: Israeli supply-chain and technology integrator serving aerospace, defense, and industrial customers across Supply Chain, RFID, and Intelligent Robotics divisions. ~$33.4M cap, $11.4M Q1 revenue.
Set-up: Q1 revenue fell to $11.4M from $15.0M, but the prior-year comp was inflated by a one-off $2.5M deal, and the call reframed the story around forward visibility: backlog grew 29% to $31M, so Q1 revenue plus backlog already covers 83% of the full-year target after one quarter, and management now expects to beat its prior $51M revenue goal. The catch is conversion — USD/NIS currency pressure is keeping the $3.6M net income target flat despite the higher revenue outlook.
Information arbitrage:
India as a repeatable channel: Indian orders jumped to $3.3M from $172K a year ago, before local representation was fully in place, hinting at a durable defense-subcontracting channel rather than a one-quarter spike.
Valuation gap management is pitching: Management compared BOS at ~book value and ~11x P/E to the Russell 2000 at ~2.6x book and ~22x P/E, signaling re-rating is now part of its capital-markets agenda.
No-dilution M&A pipeline: An active acquisition pipeline funded roughly half by bank loans and half internally, with no expected share issuance — a growth lever barely visible in the release.
Risks: EBITDA fell to $894K from $1.868M, so currency pressure means higher revenue may not convert to higher earnings; RFID profitability is volatile, and the M&A and India channels are still unproven over multiple quarters.
PYYX — Pyxus International, Inc. 🟡 Moderate Signal
Description: Global leaf-tobacco supply-chain company that sources, finances, processes, and ships tobacco leaf to the major cigarette manufacturers. ~$64.4M cap, $2.4B FY2026 revenue.
Set-up: Revenue slipped 2.8% to $2.4B on lower leaf prices, but FY2026 was really a deleveraging year — adjusted EBITDA hit a record $226.7M (fourth straight year of growth), Q4 adjusted free cash flow nearly doubled to $352.1M, and net leverage fell from over 6x at Q3 to 3.52x, a multi-year low. The striking number is the mismatch between a $64M equity value and $227M of EBITDA — a heavily levered stub where a successful debt refinancing could re-rate the equity. Management’s contrarian pitch is that the incoming tobacco oversupply can help Pyxus rather than hurt it.
Information arbitrage:
Oversupply reframed as a tailwind: Management argues lower crop costs cut inventory investment, improve fixed-cost absorption, and push more volume into third-party processing, which rose 41.1% at a 20.1% margin — the opposite of the bearish read oversupply usually gets.
Refinancing is named a top FY2027 priority: The maturity of long-term debt was flagged only on the call, not the release, turning the balance sheet into the central catalyst or overhang investors need to track.
Margin held through falling prices: Gross profit per kilo stayed near historical highs even as pricing fell, the key evidence that lower leaf prices may dent revenue without damaging EBITDA.
Risks: High debt and rising interest expense ($138.7M for the year) make the unscheduled, terms-unknown refinancing the swing factor; Q4’s 35% sales jump was partly Q3 shipments pulled forward, and 9% uncommitted inventory is a write-down risk if oversupply deepens.